Effect of levocarnitine plus iron sucrose on nutritional status and life cycle in uremic patients with renal anemia.

2025-05-01
Pakistan journal of pharmaceutical sciences 38(3)
- Li Ren
- Jun Wu
- Yanqin Shi
- Dong Li
- Gelu Huang
- Nana Meng

PubMed: 40556279
DOI: 10.36721/pjps.2025.38.3.reg.13303.1

Study Design

Type: Randomized Controlled Trial (RCT)
Sample size: n = 45
Population: 90 uremic patients with renal anemia
Methods: randomized them to an experimental group (n=45) and a control group (n=45) that were given L-carnitine+IS and L-carnitine, respectively
Duration: 1-year prognostic follow-up
Funding: Unclear

Research team believes that Levocarnitine (L-carnitine) combined with Iron sucrose (IS) has a more significant positive effect on the nutritional status and lifespan of uremic patients with renal anemia and has carried out research and demonstration based on this. First, research team selected 90 uremic patients with renal anemia admitted to our hospital from February 2019 to February 2022 and randomized them to an experimental group (n=45) and a control group (n=45) that were given L-carnitine+IS and L-carnitine, respectively. The clinical efficacy and adverse reactions of the two groups of patients were counted and fasting venous blood was collected before and after treatment to test nutrient proteins, calcium and phosphorus metabolism and renal function. In addition, 1-year prognostic follow-up was performed to count the prognostic survival of the patients. The results of the study showed that the clinical efficacy of the experimental group was better than that of the control group and the nutritional protein, calcium and phosphorus metabolism and renal function were better after treatment (P<0.05), but there was no difference in the incidence of adverse reactions between the two groups (P>0.05). Prognostic follow-up showed that there was no difference in the prognostic overall survival rate between the two groups (P>0.05), but the median survival of the experimental group was prolonged compared with the control group (P<0.05). In conclusion, L-carnitine combined with IS effectively ameliorated the anemia status of patients, improved their nutritional status and prolonged their median survival.

Research Insights

L-Carnitine→Improved Calcium and Phosphorus Metabolism
the nutritional protein, calcium and phosphorus metabolism and renal function were better after treatment (P<0.05)
Effect
Beneficial
Effect size
Moderate
L-Carnitine→Improved Clinical Efficacy
the clinical efficacy of the experimental group was better than that of the control group
Effect
Beneficial
Effect size
Moderate
L-Carnitine→Improved Renal Function
the nutritional protein, calcium and phosphorus metabolism and renal function were better after treatment (P<0.05)
Effect
Beneficial
Effect size
Moderate
L-Carnitine→Increased Serum Total Protein Levels
the nutritional protein, calcium and phosphorus metabolism and renal function were better after treatment (P<0.05)
Effect
Beneficial
Effect size
Moderate
L-Carnitine→Prolonged Median Survival Time
the median survival of the experimental group was prolonged compared with the control group (P<0.05)
Effect
Beneficial
Effect size
Moderate
L-Carnitine→Reduced All-Cause Mortality
Prognostic follow-up showed that there was no difference in the prognostic overall survival rate between the two groups (P>0.05)
Effect
Neutral
Effect size
Small

Adverse Events Reported

L-Carnitine→Overall tolerability
there was no difference in the incidence of adverse reactions between the two groups (P>0.05)
Finding
No significant difference
Significant
No